Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Vaccine|November 26, 2018
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regressionKaatje Bollaerts, Thomas Verstraeten, Catherine Cohet
Vaccine|June 11, 2018
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adultsMarc Baay, Kaatje Bollaerts, Thomas Verstraeten
Vaccine: X|August 7, 2019
Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in EnglandKaatje Bollaerts, Maria Alexandridou, Thomas Verstraeten
Archives of Public Health = Archives Belges De Sante Publique|May 7, 2013
Improved benchmark-multiplier method to estimate the prevalence of ever-injecting drug use in Belgium, 2000-10Kaatje Bollaerts, Marc Aerts, Andre Sasse
Vaccine|January 8, 2016
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among childrenJorgen Stassijns, Kaatje Bollaerts, Marc Baay, et al.
Human Vaccines & Immunotherapeutics|April 26, 2017
Background rates of disease in Latin American children from a rotavirus vaccine studyMarc Baay, Kaatje Bollaerts, Claudio Struchiner, et al.
The British Journal of Mathematical and Statistical Psychology|October 28, 2006
Simple and multiple P-splines regression with shape constraintsKaatje Bollaerts, Paul H C Eilers, Iven van Mechelen
Drug Safety|March 28, 2018
Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE ProjectKaatje Bollaerts, Tom De Smedt, Katherine Donegan, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|April 19, 2008
Human salmonellosis: estimation of dose-illness from outbreak dataKaatje Bollaerts, Marc Aerts, Christel Faes, et al.
Drug Safety|September 12, 2020
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)Hugo Arlegui, Kaatje Bollaerts, Vincent Bauchau, et al.
Pageof 5